Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) shares reached a new 52-week low on Tuesday . The company traded as low as $12.53 and last traded at $13.20, with a volume of 872657 shares traded. The stock had previously closed at $12.90.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on RCUS shares. Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Arcus Biosciences in a research note on Thursday, November 7th. Barclays raised their target price on Arcus Biosciences from $25.00 to $29.00 and gave the stock an "overweight" rating in a research report on Friday, October 25th. Finally, HC Wainwright reiterated a "neutral" rating and issued a $20.00 price target on shares of Arcus Biosciences in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $32.67.
Read Our Latest Stock Report on Arcus Biosciences
Arcus Biosciences Stock Down 3.2 %
The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The stock's 50-day simple moving average is $14.93 and its 200 day simple moving average is $15.78. The firm has a market cap of $1.15 billion, a P/E ratio of -4.00 and a beta of 0.84.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.06. The company had revenue of $48.00 million for the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm's revenue for the quarter was up 50.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.94) EPS. As a group, research analysts forecast that Arcus Biosciences, Inc. will post -3.2 EPS for the current fiscal year.
Insider Buying and Selling at Arcus Biosciences
In other news, CFO Robert C. Goeltz II sold 3,594 shares of the firm's stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the sale, the chief financial officer now directly owns 60,138 shares in the company, valued at $902,070. This trade represents a 5.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 12.30% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC lifted its holdings in shares of Arcus Biosciences by 59.8% in the 3rd quarter. Jane Street Group LLC now owns 217,041 shares of the company's stock worth $3,319,000 after purchasing an additional 81,193 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Arcus Biosciences by 11.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company's stock valued at $8,669,000 after buying an additional 59,536 shares in the last quarter. GSA Capital Partners LLP grew its holdings in shares of Arcus Biosciences by 17.8% during the third quarter. GSA Capital Partners LLP now owns 187,415 shares of the company's stock valued at $2,866,000 after buying an additional 28,307 shares during the last quarter. Parkman Healthcare Partners LLC increased its position in shares of Arcus Biosciences by 146.9% during the third quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company's stock worth $15,684,000 after acquiring an additional 610,219 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Arcus Biosciences by 7.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,858 shares of the company's stock worth $455,000 after acquiring an additional 2,123 shares during the last quarter. Institutional investors own 92.89% of the company's stock.
Arcus Biosciences Company Profile
(
Get Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Read More
Before you consider Arcus Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.
While Arcus Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
